Back to top
more

NuVasive, Inc. (NUVA)

(Delayed Data from NSDQ)

$62.96 USD

62.96
567,418

+0.74 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $62.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

NuVasive Sees Hammer Chart Pattern: Time to Buy?

NuVasive, Inc. (NUVA) has been struggling lately, but the selling pressure may be coming to an end soon.

Integra LifeSciences' Organic Growth Strong on New Products

Gaining traction from product unveilings and an improved sales force performance, Integra LifeSciences (IART) expects rapid organic growth in the second half of 2019.

Medtronic Names Next CEO as Omar Ishrak to Step Down in 2020

This is indeed a top story as during Omar's tenure, annual revenues of Medtronic (MDT) skyrocket to double-digit growth among a slew of enormous feats that he attains.

Bruker (BRKR) Releases JPK NanoWizard 4 XP Bio-AFM System

With the launch of this new system, Bruker (BRKR) establishes a performance yardstick for atomic force microscopy in the field of life science research.

Here's Why You Should Invest in Haemonetics (HAE) Right Now

Haemonetics (HAE) has been enjoying investors' rising optimism, owing to solid prospects.

Here's Why You Should Invest in Hologic (HOLX) Stock Now

Hologic (HOLX) is generating consistently positive results, thanks to impressive developments.

Zimmer Biomet Succeeds in Priority Areas, Suffers Pricing Woe

With regard to product suite, Zimmer Biomet (ZBH) steadily wins an array of key regulatory clearances for knee, brain and spine applications under its ROSA platform over the past several months.

Quest Diagnostics' New Acquisitions and Pacts Aid Growth

Quest Diagnostics' (DGX) nine deals concluded in 2018 strengthen its potential to fulfill its goals set for 2019.

Why Is NuVasive (NUVA) Down 4.2% Since Last Earnings Report?

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Medtronic (MDT) Benefits from Strength Across Business Groups

Within RTG, Medronic's (MDT) neurosurgery arm is gaining on strong uptake of Mazor X Stealth navigated robotic system.

Boston Scientific Closes BTG Buyout, PI Arm to Get a Boost

In its effort to accommodate the acquisition of BTG, Boston Scientific (BSX) is offloading its certain non-prior businesses.

NUVA vs. LZAGY: Which Stock Is the Better Value Option?

NUVA vs. LZAGY: Which Stock Is the Better Value Option?

Here's Why You Should Invest in NuVasive (NUVA) Stock Now

Investor confidence is currently high on NuVasive's (NUVA) prospects.

Smith & Nephew (SNN) Hits a 52-Week High: What's Driving It?

Smith & Nephew (SNN) has been gaining from several positive developments of late.

National Vision's Store Launches on Track Despite Cost Woes

National Vision (EYE) adopts a formula-based approach to open around 75 stores in 2019.

Abbott's Libre Adoption a Positive, Rhythm Management a Woe

Abbott (ABT) is steadily riding high on a healthy growth track within its Diabetes Care business.

Zimmer Biomet Wins Nod for Spinal Teather to Treat Scoliosis

Zimmer Biomet's (ZBH) AVBT solution, The Tether, uses a solid, flexible cord in place of traditional metal rods to pull on the outside of a scoliosis curve.

NuVasive's New TLIF Implant Broadens Spine Surgery Option

NuVasive's (NUVA) Modulus TLIF-A is designed to work smoothly with the existing MAS TLIF and MAS Midline access systems.

Genomic Health Test to Guide Chemo Per New Breast Cancer Rule

This is a major development in Genomic Health's (GHDX) endeavor to strengthen its breast cancer treatment portfolio.

Restoration Robotics (HAIR) Wins CE Mark for ARTAS iX System

This regulatory approval is expected to strengthen Restoration Robotics' (HAIR) hair restoration business and expand its presence globally.

Edwards Lifesciences' (EW) SAPIEN 3 TAVR Receives FDA Nod

Edwards Lifesciences (EW) plans a commercial introduction of SAPIEN 3 Ultra in Europe.

Here's Why You Should Hold Onto Omnicell (OMCL) Stock for Now

Investor confidence continues to be high on Omnicell's (OMCL) prospects.

QIAGEN Posts QIAstat-Dx Gastrointestinal Panel Study Results

The study outcome has been a major step for QIAGEN (QGEN) toward offering accurate diagnosis and treatment of gastroenteritis.

Baxter's PrisMax Adopted by Hamilton Health Care System

Baxter's (BAX) PrisMax System first adopted by Hamilton Health, which in turn is expected to enhance patient care.

CVS Health Banks on Health Care Benefit Prospects Amid Woes

CVS Health's (CVS) recently introduced Health Care Benefits segment following the Aetna acquisition is gaining a strong momentum.